News

FDA halts Rocket Pharma's gene therapy trial as patient dies
The U.S. FDA has paused Rocket Pharmaceuticals' mid-stage gene therapy trial after a patient died from serious complications, ...
Fierce Biotech10d
Rocket crashes as gene therapy patient dies, FDA imposes hold
The FDA has slapped a clinical hold on Rocket Pharmaceuticals’ pivotal gene therapy trial in response to a death. Rocket, ...
Rocket Pharmaceuticals: Despite FDA Clinical Hold On RP-A501, Prospects Remain Intact
FDA places clinical hold of RP-A501 for the treatment of patients with Danon disease due to a patient death. Click here to ...
Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold
Rocket Pharmaceuticals halted its Danon disease gene therapy trial after a patient death, with the FDA placing the study on ...
BioSpace11d
Rocket’s Danon Disease Gene Therapy on Hold After Patient Death
Acute systemic infection caused the patient to develop fatal capillary leak syndrome, highlighting the unpredictability of ...
Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies
Rocket Pharmaceuticals shares plummeted 60% Tuesday after the firm said it halted a study of a gene-therapy drug for Danon ...
MedCity News10d
Death in Rocket Pharma Gene Therapy Study Puts Spotlight on Trial Change Intended to Improve Safety
A patient has died in a clinical trial evaluating a Rocket Pharmaceuticals gene therapy shortly after complications emerged that led the FDA to pause the study. An inquiry into the fatality is ...
Devdiscourse11d
Global Health Updates: Supply Shortages and Innovations in Focus
This content summarizes the latest health news, highlighting critical shortages of medical supplies in Gaza, launching a ...
Pharmabiz10d
US FDA places clinical hold on Rocket Pharma's gene therapy phase 2 trial of RP-A501 to treat Danon disease
US FDA places clinical hold on Rocket Pharma's gene therapy phase 2 trial of RP-A501 to treat Danon disease: Cranbury, New Jersey Wednesday, May 28, 2025, 14:00 Hrs [IST] Rocket P ...
Seeking Alpha11mon
Rocket falls as FDA rejects gene therapy Kresladi
Rocket Pharmaceuticals (NASDAQ:RCKT) lost ~14% premarket Friday after announcing that the U.S. Food and Drug Administration (FDA) declined to approve its gene therapy candidate Kresladi ...
Reuters11mon
US FDA declines to approve Rocket Pharma's immune disorder gene therapy
Analysts at TD Cowen had then said the delay seemed to be an FDA bandwidth-related issue and not an issue at the company's end. Kresladi is a small opportunity for Rocket, but success here will ...
FDA halts Rocket Pharma's gene therapy trial as complications lead to patient death
The U.S. FDA has paused a mid-stage gene therapy trial by Rocket Pharmaceuticals after a patient suffered serious ...